BridgeBio Pharma Inc (BBIO)

BridgeBio Pharma Inc 주식(BBIO)의 최신 뉴스

Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down

Zacks Investment Research

Dr. Reddy's (RDY) Q4 Earnings Top, North America Sales Grow

Zacks Investment Research

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

GlobeNewswire Inc.

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Zacks Investment Research

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

GlobeNewswire Inc.

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

Zacks Investment Research

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

GlobeNewswire Inc.

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

GlobeNewswire Inc.

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday

Benzinga

Analysts Estimate BridgeBio Pharma (BBIO) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

GlobeNewswire Inc.

BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

GlobeNewswire Inc.

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

GlobeNewswire Inc.

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

GlobeNewswire Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

GlobeNewswire Inc.

2 Biotechs That Could Get Bought Out in 2024

The Motley Fool

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

The best-performing stock of the year rose nearly 10-fold, while the 2nd-best averted disaster to surge 1,000% in a wild 2023

MarketWatch

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

GlobeNewswire Inc.

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

GlobeNewswire Inc.

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

GlobeNewswire Inc.